| Literature DB >> 28804720 |
Mitra Deylam Salehi1, Elaheh Ferdosi-Shahandashti2, Yosef Yahyapour3, Soraya Khafri4, Abazar Pournajaf5, Ramazan Rajabnia3.
Abstract
BACKGROUND: We investigated the integron types and their relation with antibiotic resistance among A. baumannii isolates collected from intensive care unit patients, Babol, north of Iran.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28804720 PMCID: PMC5540380 DOI: 10.1155/2017/7157923
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Primer sequences, PCR product sizes, and PCR programs for replication of class I, II, and III integrons.
| Genes | Primer sequence (5′ → 3′) | PCR product (bp) | PCR program | Reference |
|---|---|---|---|---|
|
| F-TCTCGGGTAACATCAAGG | 243 | 5 min at 94°C; 35 cycles (1 min at 94°C, 1 min at 53°C, and 30 sec at 72°C); 5 min at 72 | [ |
|
| ||||
|
| F-TTATTGCTGGGATTAGGC | 233 | 5 min at 94°C; 30 cycles (1 min at 94°C, 1 min at 50°C, and 1 min at 72°C); 10 min at 72° | [ |
|
| ||||
|
| F-AGTGGGTGGCGAATGAGTG | 600 | 5 min at 94°C; 30 cycles (1 min at 94°C, 1 min at 50°C, and 1 min at 72°C); 10 min at 72°C | [ |
Bacterial etiologic agents.
| Agents | All BALs | ||
|---|---|---|---|
| Mono (%) | Poly (%) | Total (%) | |
|
| 30 (41.1%) | 5 (6.8%) | 35 (48%) |
|
| 3 (4.1%) | 1 (1.9%) | 4 (5.5%) |
|
| 2 (2.7%) | 2 (2.7%) | 4 (5.5%) |
|
| 1 (1.4%) | 0 (0.0%) | 1 (1.4%) |
|
| 0 (0.0%) | 1 (1.4%) | 1 (1.4%) |
|
| 0 (0.0%) | 1 (1.4%) | 1 (1.4%) |
|
| 0 (0.0%) | 2 (2.7%) | 2 (2.7%) |
|
| 1 (1.4%) | 0 (0.0%) | 1 (1.4%) |
| MRCoNS | 1 (1.4%) | 0 (0.0%) | 1 (1.4%) |
|
| 2 (2.7%) | 0 (0.0%) | 2 (2.7%) |
Mono = unique isolated agent; Poly = polymicrobial infection; MRCoNS = methicillin resistant coagulase-negative Staphylococcus.
Antibiotics resistance patterns among Acinetobacter isolates.
| Antibiotics | R (%) | I (%) | S (%) |
|---|---|---|---|
| Amikacin (AN) | 32 (91.4) | 0 (0.0) | 3 (8.6) |
| Gentamicin (GM) | 30 (85.7) | 1 (2.9) | 4 (11.4) |
| Ciprofloxacin (CP) | 33 (94.3) | 0 (0.0) | 2 (5.7) |
| Ceftazidime (CAZ) | 35 (100) | 0 (0.0) | 0 (0.0) |
| Imipenem (IPM) | 33 (94.3) | 2 (5.7) | 0 (0.0) |
| Meropenem (MEN) | 33 (94.3) | 1 (2.9) | 1 (2.9) |
| Piperacillin-tazobactam (PIP-TZ) | 32 (91.4) | 1 (2.9) | 2 (5.7) |
I = intermediate; R = resistance; S = susceptible.
Figure 1E-test MIC value of colistin. (a) Colistin-susceptible A. baumannii (interpretative criteria; susceptible (S), ≤2 μg/ml). (b) Colistin-resistant A. baumannii (interpretative criteria; resistant (R), ≥4 μg/ml). Colistin sulfate (CS), ranging from 0.016 to 256 mg/ml produced by Liofilchem SRL, Roseto degli Abruzzi, Italy.
The correlation of class I, II, and III integrons and antibiotic resistance profile.
| Antibiotics | Positive for integron class I ( | Negative for integron class I ( |
| OR (95 CI) | Positive for integron class II ( | Negative for integron class II ( |
| OR (95 CI) | Positive for integron class III ( | Negative for integron class III ( |
| OR (95 CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AN | ||||||||||||
| R | 9 (25.7%) | 23 (65.7) | 0.287 | 1.666 (0.138–90.16) | 30 (85.7) | 2 (5.7) | 0.002 | 30 (0.915–182) | 10 (28.6) | 22 (62.9) | 0.252 | 1.913 (0.159–102) |
| I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
| S | 0 (0) | 3 (8.6) | 1 (2.9) | 2 (5.7) | 0 (0) | 3 (8.6) | ||||||
|
| ||||||||||||
| GM | ||||||||||||
| R | 7 (20) | 23 (65.7) | 0.430 | 2.190 (0.303–15.851) | 28 (80) | 2 (5.7) | 0.030 | 9.33 (0.457–159.29) | 10 (28.6) | 20 (57.2) | 0.127 | 3.142 (0.307–157.47) |
| I | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | ||||||
| S | 1 (2.9) | 3 (8.6) | 2 (5.7) | 2 (5.7) | 0 (0) | 4 (11.4) | ||||||
|
| ||||||||||||
| CP | ||||||||||||
| R | 8 (22.6) | 25 (71.4) | 0.418 | 3.125 (0.175–55.886) | 31 (88.6) | 4 (11.4) | 0.000 | 31 (1.576–1675.56) | 9 (25.7) | 24 (68.6) | 0.357 | 1.375 (0.963–78.648) |
| I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
| S | 1 (2.9) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | 1 (2.9) | ||||||
|
| ||||||||||||
| CAZ | ||||||||||||
| R | 9 (25.7) | 26 (74.3) | 0.004 | — | 31 (88.6) | 4 (11.4) | 0.000 | — | 10 (28.6) | 25 (71.4) | 0.011 | — |
| I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
| S | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
|
| ||||||||||||
| IPM | ||||||||||||
| R | 8 (22.9) | 25 (71.4) | 0.418 | 3.125 (0.175–55.886) | 31 (88.6) | 2 (5.7) | 0.000 | 32 (2.484–15570.62) | 9 (25.7) | 24 (68.5) | 0.490 | 2.6667 (0.150–47.302) |
| I | 1 (2.9) | 1 (2.9) | 0 (0) | 2 (5.7) | 1 (2.9) | 1 (2.9) | ||||||
| S | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
|
| ||||||||||||
| MER | ||||||||||||
| R | 9 (25.7) | 24 (68.6) | 0.392 | 1.2 (0.836–69.206) | 31 (88.6) | 2 (5.7) | 0.000 | 32 (2.484–15570.62) | 10 (28.6) | 23 (65.7) | 0.357 | 1.375 (0.963–78.648) |
| I | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | ||||||
| S | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | ||||||
|
| ||||||||||||
| PIP-TZ | ||||||||||||
| R | 8 (22.9) | 24 (68.6) | 0.757 | 1.50 (0.119–18.836) | 31 (88.6) | 1 (2.9) | 0.000 | 32 (2.484–15570.62) | 9 (25.7) | 23 (65.7) | 0.849 | 1.278 (0.103–15.899) |
| I | 0 (0) | 1 (2.9) | 0 (0) | 2 (5.7) | 0 (0) | 1 (2.9) | ||||||
| S | 1 (2.9) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | 1 (2.9) | ||||||
AN: amikacin, GM: gentamicin, CP: ciprofloxacin, CAZ: ceftazidime, IPM: imipenem, MER: meropenem, PIP-TZ: piperacillin-tazobactam, R: resistance, I: intermediate, S: sensitive, and OR: odds ratio.